Latest Articles
Lactate metabolism and lactylation in female reproductive diseases: From metabolic rewiring to biomarkers and translational therapeutics.
Lactate is increasingly recognized not only as a metabolic end product of glycolysis but also as a signaling metabolite that links metabolic reprogramming to epigenetic and transcriptional regulation through protein …
Published: June 17, 2026, midnight
Faeth Therapeutics Rebrands, Relocates and Overhauls Leadership - The Globe and Mail
Faeth Therapeutics Rebrands, Relocates and Overhauls Leadership The Globe and Mail
Published: June 16, 2026, 1:17 p.m.
Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline - The Manila Times
Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline The Manila Times
Published: June 11, 2026, 7:39 a.m.
Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline - GlobeNewswire
Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline GlobeNewswire
Published: June 11, 2026, 7:30 a.m.
p16 Beyond Senescence: Cancer Biology Lessons Applied to Endometriosis.
Endometriosis is an estrogen-dependent disease characterized by chronic inflammation and fibrosis and is a major cause of pelvic pain and infertility. Recent studies have reported dysregulated expression of p16INK4a, a …
Published: June 11, 2026, midnight
Surgical Treatment Experience of Intestinal Endometriosis.
Retrospective descriptive cohort.
Published: June 1, 2026, midnight
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com UK
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline Investing.com UK
Published: May 21, 2026, 8:34 p.m.
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline - Investing.com
Acrivon Therapeutics’ SWOT analysis: stock shows promise in cancer pipeline Investing.com
Published: May 21, 2026, 2:57 p.m.
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - BioSpace
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update BioSpace
Published: May 18, 2026, 1:17 a.m.
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor - Femtech Insider
Maipl Therapeutics Advances Non-Hormonal Oral Endometriosis Therapy Targeting Prostaglandin F2α Receptor Femtech Insider
Published: May 15, 2026, 11:33 a.m.
Link copied to clipboard!